Additionally, the MM patients with TP53L and concomitant NEK2H expression had a significantly inferior OS (median, 40.8 months), while patients with either NEK2L or TP53H had better outcomes (TP53H & NEK2L and TP53L & NEK2L, not reached; TP53H & NEK2H, 49 months; Figure 2F). Here, TP63 is linked to Miyoshi myopathy.